Eliopoulos Anastasia, Rivera Beatrice, McCullough Emily, Singh Ameeta E, Gratrix Jennifer, Tipples Graham, Zhou Hong Yuan, Galli Rick, Rourke Sean B, Fonseca Kevin
Public Health Laboratory, Alberta Precision Laboratories, Calgary, Alberta, Canada.
Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Alberta, Canada.
Microbiol Spectr. 2025 Jul;13(7):e0013225. doi: 10.1128/spectrum.00132-25. Epub 2025 May 19.
Syphilis, a sexually transmitted infection, is resurging with large outbreaks worldwide. In pregnant females, vertical transmission can result in stillbirths and serious sequelae for the fetus. Syphilis serology is primarily used to make the diagnosis, but the testing platforms and confirmatory tests are often centralized; therefore, the time to a result is usually more than 2 days. Most affected populations in the current outbreaks can be transient and easily lost to follow up. Therefore, rapid testing can assist with timely detection, treatment, and linkage to care. We evaluated the performance of the INSTI Multiplex HIV-1/2 Syphilis rapid test, using a large panel of negative and confirmed positive sera with varying rapid plasma reagin (RPR) titers. Sera with RPR titers of 1:8 and greater consistently gave a positive rapid test result (93.8%-100%; 95% CI: 82.5%-100%), whereas samples with RPR titers of 1:2 and lower were often negative (7.6%-56.5%). Rapid test positive samples generally had a syphilis CMIA S/CO ratio of 19.78 and higher, although there was no specific ratio that separated all positive from negative rapid results. In infectious syphilis, RPR titers are often 1:8 and greater and should be reliably detected with this rapid test (accuracy 97.2%), thereby supporting immediate treatment and linkage to care with a high level of confidence. Additionally, a result is available within minutes and therefore could be included on acute care STAT laboratory test menus while the individual is an in-patient or awaiting assessment in the Emergency Department.
We examined the performance of the syphilis antibody component of a rapid multiplex device and found that sera with RPR titers of 1:8 and greater, often found in infectious syphilis, were highly likely to test positive. This device would be suitable for providing STAT syphilis serology testing for suspect cases waiting in the Emergency Department or as inpatients. Positive results can support immediate treatment and linkage to care, especially for pregnant females and transient persons who are often lost to follow up.
梅毒是一种性传播感染疾病,目前在全球范围内正随着大规模疫情的爆发而卷土重来。在怀孕女性中,垂直传播可导致死产以及胎儿出现严重后遗症。梅毒血清学主要用于进行诊断,但检测平台和确证试验往往集中进行;因此,获得检测结果的时间通常超过2天。当前疫情中大多数受影响人群可能是流动人口,很容易失去随访。因此,快速检测有助于及时发现、治疗并提供护理服务。我们使用大量不同快速血浆反应素(RPR)滴度的阴性和确诊阳性血清,评估了INSTI多重HIV-1/2梅毒快速检测的性能。RPR滴度为1:8及以上的血清始终给出快速检测阳性结果(93.8%-100%;95%置信区间:82.5%-100%),而RPR滴度为1:2及以下的样本通常为阴性(7.6%-56.5%)。快速检测阳性样本的梅毒化学发光微粒子免疫分析(CMIA)S/CO比值一般为19.78及以上,不过并没有一个特定比值能区分所有快速检测阳性和阴性结果。在感染性梅毒中,RPR滴度通常为1:8及以上,使用这种快速检测应能可靠检测到(准确率97.2%),从而支持立即进行治疗并高度自信地提供护理服务。此外,几分钟内就能获得检测结果,因此可以纳入急症护理的急诊实验室检测项目,适用于患者住院期间或在急诊科等待评估时。
我们检测了一种快速多重检测设备的梅毒抗体成分的性能,发现RPR滴度为1:8及以上的血清(常在感染性梅毒中出现)极有可能检测为阳性。该设备适用于为在急诊科等待的疑似病例或住院患者提供急诊梅毒血清学检测。阳性结果可支持立即进行治疗并提供护理服务,特别是对于怀孕女性和经常失去随访的流动人口。